Dr. Hira Nakhasi is currently the Director of the Division of Emerging and Transfusion Transmitted Diseases (DETTD) at the Center for Biologics Evaluation and Research (CBER) of the US Food and Drug Administration. As the Director of the DETTD, he is responsible for approving assays to screen blood donors for blood borne pathogens and retroviral diagnostic to ensure USA blood safety. He received his Masters and Ph.D. degrees in biochemistry from the M.S. University of Baroda, India and postdoctoral training at the National Institutes of Health, Bethesda, Maryland and Columbia University, New York, USA.
His scientific expertise lies in molecular virology, parasitology, cell biology, immunology and vaccinology. His main research is focused on Leishmania pathogenesis and develop methods to evaluate safety and efficacy genetically modified Leishmania vaccines and diagnostic tools.
He has published over 150 publications including reviews and book chapters, being a member of the review committees of several high impact journals, reviewer of grants, and being invited to speak at national and international forums. He is also a member of the several scientific organizations. Over the years he has received numerous awards including US Department of Human and Health Services Distinguished Service Award. Recently he was elected to be the Fellow of American Society of Tropical Medicine and Hygiene. He also has been recipient of several grants from International agencies such as Global Health Initiative and Technologies, Japan; Wellcome Trust UK and National Institutes of Health, USA worth millions of dollars for his studies on Leishmania vaccine development.